Mr Matsuda joined Arcutis in January 2022 as general counsel and corporate secretary. He is responsible for all legal and compliance for the company, as well as serving as secretary of the board of directors. Mr Matsuda previously served as senior vice president, general counsel, chief compliance officer, and corporate secretary at Halozyme Therapeutics, Inc. Prior to Halozyme, Mr Matsuda worked at Amgen for 18 years in positions of increasing responsibility with his last role serving as vice president, Law, Global Commercial Operations, where he was responsible for strategic commercial legal support to the US Commercial Operations organization, as well as Medical Affairs, Compliance, Global Value, Access & Policy, Global Marketing, and Biosimilars divisions. Mr Matsuda received a Bachelor of Science in Business Administration with a dual emphasis in Corporate Finance and International Finance from the University of Southern California, and a Juris Doctorate from University of California, Hastings College of the Law.

Mr Madan brings over 20 years of digital transformation and innovation experience to the Arcutis team. Prior to joining Arcutis, Mr Madan served as the vice president of digital, data/analytics and innovation for consumer healthcare technology at GlaxoSmithKline (GSK), where, in partnership with the chief digital officer, he was responsible for driving significant elements of their digital and tech transformation globally. Before GSK, Mr Madan was with Novartis where he was responsible for managing and delivering global, regional, and localized digital solutions and services across 3 business units and in more than 80 countries. In addition to healthcare, Mr Madan has experience in the consumer goods sector, having spent 14 years at L’Oreal in various roles, including managing the digital tech function for L’Oreal Americas. Mr Madan holds a bachelor’s degree in computer engineering from the New Jersey Institute of Technology and master’s degrees in both business administration and information systems from New York University Stern School of Business.

Prior to becoming chief financial officer in April 2021, Mr Burrows served as Arcutis’ vice president of finance since joining the Company in May 2019. Prior to Arcutis, Mr Burrows was the head of international investor relations for Shire, plc in Zug, Switzerland, where he played a key role in gathering European and Japanese investor support for Takeda’s acquisition of Shire. Prior to Shire, he spent 15 years at Amgen, Inc. in roles of increasing responsibility across financial planning and analysis, treasury, and investor relations. Mr Burrows started his career as a consultant at Arthur Andersen. He earned both his BA and MBA from the University of California, Los Angeles, and is a licensed CPA in California (inactive).

Matthew Moore joined Arcutis as chief business officer in January 2021. Mr Moore has over 20 years of strategy, transaction, and operations experience in the biopharmaceutical industry. Most recently, he served as vice president, corporate business development and alliance management at Allergan, where he led worldwide strategy and business development for the company’s $4 billion+ medical aesthetics business unit.

During his tenure at Allergan and its predecessor companies, Actavis and Forest Labs, Mr Moore was responsible for creating and executing business development growth strategies across multiple therapeutic areas including medical aesthetics, neuroscience, anti-infectives, and hospital products. In addition, Mr Moore served as a key deal team member in Actavis’ transformational acquisition of Allergan and Allergan’s ultimate sale to AbbVie. Prior to Allergan, Mr Moore held executive roles at DOV Pharmaceutical and he started his career in the healthcare investment banking group at CIBC Oppenheimer. Mr Moore earned his BA in psychology from Trinity College.

Patrick Burnett has served as Arcutis’ chief medical officer since August 2020. Prior to that, Dr Burnett was the chief medical officer at Verrica Pharmaceuticals since April 2018. Prior to that, Dr Burnett was at Sun Pharmaceuticals where he was associate vice president of clinical development from September 2015 to March 2018, with oversight of the dermatology and rheumatology pipeline. Prior to Sun, Dr Burnett was at Novartis from 2010 to August 2015, most recently as global program medical director. He is a board-certified dermatologist and was a member of the medical faculty at Vanderbilt University Medical Center as an assistant professor of dermatology from 2004 to 2010. Dr Burnett holds an MD and PhD in neuroscience from Johns Hopkins School of Medicine and a BS in biology and biochemistry from the University of Iowa.

Ms Turney has served as our senior vice president, operations since January 2020. She previously worked at Amgen, Inc. from 1996 to 2019 in roles of increasing responsibility, most recently as vice president, external supply, where she managed more than 50 contract manufacturing sites supporting clinical programs and commercial products. Prior Amgen roles included: executive director, medical device and direct materials; site operations head for Amgen’s Netherlands site; executive director, global facilities operations; and director, R&D strategic operations. Prior to joining Amgen, Ms Turney was a Federal Aviation Administration certified instructor, and earlier, a naval aviator in the United States Navy. She holds a Bachelor of Science in mathematics from the United States Naval Academy and a Master of Business Administration from the Anderson School, University of California, Los Angeles.

Ken Lock has served as our chief commercial officer since October 2019. Prior to joining Arcutis, he served as the executive director of sales and marketing at Gilead Sciences, concurrently leading the inflammation and pulmonary hypertension US commercial franchises from December 2013 to August 2019. Prior to Gilead, Mr Lock was employed at Amgen, Inc. from March 2007 to November 2013, where he was involved in the prelaunch global development of Repatha® for hyperlipidemia and also held US brand marketing and sales leadership roles for Enbrel® for rheumatoid arthritis and psoriasis. From June 2003 to February 2007, Mr Lock was at Wyeth Pharmaceuticals where he held various positions including strategic planning, international commercial operations, and marketing for Enbrel® in both rheumatology and dermatology. He started his career in process development and biologics manufacturing at IDEC Pharmaceuticals in 1996. Mr Lock received both his BS in biochemistry/cell biology and BA in psychology from University of California, San Diego, and completed his MBA at Cornell University.

Dr Osborne is one of the co-founders of Arcutis, and is a prominent expert in pharmaceutical product development, specializing in the topical, transdermal, transmucosal, and subcutaneous delivery of active pharmaceutical ingredients through creams, gels, and ointments. Prior to Arcutis, he was chief scientific officer at Tolmar, and before that, vice president of product development at Dow Pharmaceutical Sciences, and earlier, ViroTex/Atrix. He started his career as a formulation group leader at The Upjohn Company and then a Merck subsidiary.

Dr Osborne has 29 issued US patents, is a named inventor on 4 FDA-approved topical products, and led the development of Eligard®, Clobex® Spray, MetroGel® 1%, and 15 generic topical products. He has 58 publications, primarily in the areas of surfactants, formulations, and skin delivery, and edited 2 books on topical drug development. He was the 1992 chairman of the ACS Division of Colloid and Surface Chemistry, and founding North American editor of the journal Colloids and Surfaces: Biointerfaces. He received his BSc in chemistry from Missouri State University, and a PhD in physical chemistry from Missouri Science and Technology.

Mr Watanabe has been the president of Arcutis since 2016, and chief executive officer since 2017. Prior to joining Arcutis, he was co-founder and chief operating officer of Kanan Therapeutics, a cardiovascular drug development company, and before that, was vice president of strategy and corporate development at Kythera Biopharmaceuticals.

Mr Watanabe was an executive at Amgen, Inc. from 2005 to 2013, where he was involved in the development of Repatha® for hyperlipidemia and Aimovig® for migraine, and worked on the US marketing of Enbrel® in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and Company, and an official in the US government. He was also a commissioned officer in the US Navy Reserves for 25 years. He formerly served on the board of Amunix Pharmaceuticals. Mr Watanabe earned his MA in national security studies, and his BA in international relations, both at Georgetown University.

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download